Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development

Combination Therapy

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

NEJM publication with ESMO presentation positions the regimen for stronger guidelines, with manageable safety tradeoffs.

Cancer drug pair extends mouse lifespan by 30% as researchers plan human trials